PIPR

Analyst Note: PIPR (Piper Sandler Companies)

Date: 2026-06-13 Subject: Structural Setup Analysis & Business Fundamentals

1. Structural Readiness

Current State: FORMING

• Conservative Entry: $94.07
• Current Price: $81.80
• Extension: -13.0% vs. conservative entry (indicating the price is currently in a pullback or consolidation phase relative to the breakout target).
• Volatility Context: The ATR at the potential breakout was 2.6% (productive), and current ATR is 3.0% (productive). This volatility profile suggests the stock has sufficient structural quality to move, but the current price action is testing the lower bound of the coil structure.

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Macro Thesis Status: None Named. As of 2026-06-13, there is no named secular thesis driving this specific setup. The investment case is not derived from a broad macro narrative (e.g., "rate cut beneficiary" or "AI infrastructure boom") but is strictly driven by the quality of the technical structure (the Coil) and the underlying business fundamentals. The conviction must be derived entirely from the setup quality and the company's operational performance, not from an invented macro theme.

3. Business Fundamentals

Company Overview: Piper Sandler Companies operates as a well-established investment bank and institutional brokerage, founded in 1895. The firm provides a comprehensive array of financial solutions to corporations, private equity groups, public entities, non-profit entities, and institutional investors in the U.S. and internationally. Its primary services encompass investment banking, institutional sales, trading, and research across both equity and fixed income markets.

Operational Highlights (Source: Q1 2026 Earnings & 10-K filings):

• Revenue Performance: For the three months ended March 31, 2026, advisory services revenues were $251.0 million, up 15.8% compared to $216.8 million in Q1 2025. This growth was driven primarily by more completed transactions.
• Sector Leadership: The Healthcare franchise produced an exceptionally strong quarter, setting a new high watermark in revenues. The firm served as book runner on all 23 completed healthcare equity deals in the quarter.
• Capital Markets Activity: In Q1 2026, the firm completed 36 equity, debt, and preferred financings, raising $14 billion for corporate clients. Additionally, they underwrote 98 municipal negotiated transactions, raising $3 billion of par value.
• Workforce Expansion: The firm finished the quarter with 192 investment banking managing directors, the highest number in firm history, signaling an aggressive expansion of capacity to capture deal flow.
• Research Coverage: Fundamental equity research analysts provide investment ideas and support to trading clients on approximately 840 companies.

Management Expectations (Recorded as of May 2026):

• Q2 Advisory: Management expects second-quarter advisory revenues to be similar to the first quarter.
• Q2 Corporate Financing: Management anticipates a decline in corporate financing revenues from the strong first quarter.
• Q2 Overall Revenue: Management expects second-quarter revenues to improve modestly from the first quarter, aligning with typical seasonality, though they also noted a general expectation that Q2 revenues will decline from the record Q1 levels.
• Q2 Municipal: Management anticipates municipal financing revenues will improve modestly from the first quarter.
• Q2 Brokerage: Management expects equity brokerage revenues to decline from first-quarter levels, correlating with market volatility and trading volumes.
• Macro Outlook: Management views the near-term macroeconomic environment as uncertain but describes the overall market backdrop as constructive, citing strong equity markets, solid corporate investment banking activity, and a more accommodative regulatory environment.

4. Archetype and Conviction Stack

Archetype: Margin Inflector The "Margin Inflector" archetype fits PIPR as the firm is leveraging its expanded capacity (192 MDs, highest in history) and sector-specific dominance (Healthcare) to drive revenue growth and improve operating leverage. The expansion of the managing director headcount suggests a strategic bet on capturing more deal flow, which, if realized, should inflect margins as fixed costs are absorbed by higher transaction volumes.

Conviction Stack Analysis:

• Thesis Strength: Low (Tactical Only). No secular macro thesis is present; the case is purely setup and business-led.
• Evidence Quality: High. The evidence base is robust, citing specific Q1 2026 financials, transaction counts, and clear management guidance for Q2. The data points to a strong Q1 followed by a seasonal normalization.
• Structural Quality: Productive. The ATR metrics (2.6% at breakout, 3.0% current) fall within the "productive" bucket, indicating the stock has the volatility necessary for a move but is not in an extreme "severe loser" zone (>8%).
• Rerating Potential: Moderate. The rerating potential depends on the successful execution of the Q2 guidance (modest improvement) and the ability to maintain the momentum in the Healthcare franchise. The "constructive" macro backdrop noted by management supports this, but the lack of a named secular thesis limits the ceiling of the rerating narrative.

5. Invalidations, Strengtheners, and Gaps

Invalidation Criteria:

• Fundamental: A significant deviation from management's Q2 guidance (e.g., a sharp decline in advisory revenues rather than "similar" or "modest improvement") or a failure to maintain the Healthcare franchise's high watermark.

Strengtheners:

• Technical: A daily close above the conservative entry of $94.07, confirming the breakout and transitioning the coil to "Confirmed-Active."
• Fundamental: Confirmation that the "constructive" macro backdrop is driving higher-than-expected deal flow in Q2, specifically in the Healthcare or Municipal sectors.

Evidence Gaps:

• Valuation Context: While the financial spine provides forward consensus EPS estimates ($4.72 for FY1, $5.64 for FY2), there is no explicit P/E or P/Book valuation context provided in the evidence block to compare against historical averages or peers.
• Q2 Actuals: As of 2026-06-13, Q2 2026 results are not yet reported; the analysis relies entirely on management's *expectations* recorded in May.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" state and current price extension of -13%. Expected horizon: 1 to 3 months for the setup to resolve (either breakout or invalidation). Failure mode to watch: A daily close below $80.81, which would confirm the coil is invalidated and the structural thesis is broken.